Team

Management

Tom Johnston

Thomas Johnston
Chief Executive Officer
Mr. Thomas Johnston is Chief Executive Officer. Mr. Johnston joined Mucosis in May 2011 from Novavax where as Vice President of Strategy he developed and executed a regional partnership strategy with deals in India, Mexico, and South Korea. Prior to Novavax, Mr. Johnston served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.

Kees Leenhouts

Cornelis J. Leenhouts, Ph.D.
Chief Scientific Officer
Dr. Kees Leenhouts is a co-founder and Chief Scientific Officer of Mucosis. Previously, Dr. Leenhouts was program manager at Biomade Technology Foundation, and responsible for intranasal vaccine technology development. He spent two years as research fellow at the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy. Dr. Leenhouts is inventor of the Mimopath® technology. He holds a Ph.D. in biology from the University of Groningen.

Roberto Grimaldi

Roberto Grimaldi
Chief Medical Officer
Dr. Grimaldi was appointed Chief Medical Officer of Mucosis in April 2010.  He is an accomplished executive and consultant to the vaccine industry who brings over 25 years of experience to lead the Mucosis development programs into clinical trials in the near future. Before joining Mucosis as Chief Medical Officer, Dr. Grimaldi was Executive Vice President at Crucell , responsible for product development and regulatory affairs. He has held several senior positions amongst others in Chiron Vaccines, Pharmacia & Upjohn, Sandoz and Farmitalia Carlo Erba. Dr. Grimaldi holds a degree in medicine and surgery from the University of Pavia (Italy), and is specialized in clinical pharmacology.

Roberto Grimaldi

Jolande Schoemaker
QA Director
Ms. Schoemaker has been an independent consultant acting as head of Quality Affairs and Qualified Person for Mucosis since 2007. Prior to her work with Mucosis, she was Head of Quality at Crucell also a founder of MicroSafe.  Ms. Schoemaker studied Pharmacy at the Univeristy of Groningen, the Netherlands and Specialization clinical Pharmacy at Slotervaartziekenhuis, Amsterdam.

Supervisory Board

John Lambert

John Lambert
Chairman of the supervisory board
In a career spanning some 35 years, John has held various Chairman, CEO, President and Board positions in public and private life-science companies in the U.K., the U.S., Europe and major international countries. This includes Presiding over such companies as Aventis Pasteur MSD and Chiron Vaccines. During his career John has always set out to implement strategies to dramatically improve the performance and profitability of his companies. John has also been the elected representative of the global vaccine industry on international Boards promoting immunisation and healthcare worldwide. .

Barry Buckland

Barry C. Buckland
Member of the supervisory board
PhD in Biochemical Engineering at University College London obtained in 1974. Joined the Merck Research Laboratories (MRL) in 1980 and built a world class Bioprocess R&D group. Leader of process development of all biologically made product candidates within the MRL pipeline and manufacture of Clinical Supplies during the past 20 years. Products developed within this timeline include MEVACOR®, ZOCOR®, IVOMEC®, CANCIDAS®, RECOMBIVAX HB®, VAQTA®, VARIVAX®, COMVAX®., ROTATEQ® (Rotavirus vaccine), ZOSTAVAX® (shingles vaccine) and GARDASIL® (HPV vaccine).

Willem Hazenberg

Willem Hazenberg Ph.D.
Member of the supervisory board
Dr. Hazenberg served as chairman of the supervisory board since August 2007. He is partner at BioGeneration Ventures B.V., an early stage Life Sciences venture capital fund with a focus on The Netherlands. He has entrepreneurial experience in creating and working with a large number of start-up companies in the sector.

Otto Postma

Otto H. Postma M.Sc.
Member of the supervisory board
Mr. Postma served as member of the supervisory board since August 2007. He is senior investment manager at MedScience Capital B.V. He co-founded (the predecessor of) Pharming Group N.V., founded and managed Pharming Healthcare, Inc., and was instrumental in the establishment or early development of several Dutch life sciences start-ups.

Annemieke Wouterse

Annemieke J. Wouterse drs. RC
Member of the supervisory board
Ms. Wouterse served as member of the supervisory board since September 2010. She is senior investment manager at N.V. NOM, Investment and Development Company for the Northern Netherlands. She has a financial background and is involved with several highly innovative companies in the region.

07.11.16 Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine
more >

24.03.16 Mucosis to Present at World Vaccines Congress 2016
more >

20.01.16 Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
more >

19.05.15 Mucosis to Present Data on Intranasal RSV Vaccine SynGEM® at Modern Vaccines Adjuvants & Delivery Systems 2015
more >

23.03.15 Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe
more >

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >